HK1108312A1 - Medical use and composition for the treatment of lipid and glucose metabolism disorders - Google Patents
Medical use and composition for the treatment of lipid and glucose metabolism disordersInfo
- Publication number
- HK1108312A1 HK1108312A1 HK07110914.5A HK07110914A HK1108312A1 HK 1108312 A1 HK1108312 A1 HK 1108312A1 HK 07110914 A HK07110914 A HK 07110914A HK 1108312 A1 HK1108312 A1 HK 1108312A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lipid
- treatment
- agonist
- glucose metabolism
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1737796P | 1996-05-07 | 1996-05-07 | |
US1933696P | 1996-06-06 | 1996-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1108312A1 true HK1108312A1 (en) | 2008-05-02 |
Family
ID=26689794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07110914.5A HK1108312A1 (en) | 1996-05-07 | 2007-10-09 | Medical use and composition for the treatment of lipid and glucose metabolism disorders |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0934069B1 (xx) |
AT (1) | ATE344668T1 (xx) |
CA (1) | CA2254116C (xx) |
DE (1) | DE69736928T2 (xx) |
DK (1) | DK0934069T3 (xx) |
ES (2) | ES2277357T3 (xx) |
HK (1) | HK1108312A1 (xx) |
PT (1) | PT934069E (xx) |
WO (1) | WO1997041873A1 (xx) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6366298B1 (en) | 1999-06-03 | 2002-04-02 | Netzero, Inc. | Monitoring of individual internet usage |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
AU2013263800B2 (en) * | 2007-03-30 | 2016-05-05 | Veroscience Llc | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
EP2217067A4 (en) * | 2007-11-07 | 2011-01-19 | Burnham Inst Medical Research | METHOD AND COMPOUNDS FOR MODULATING INSULIN PRODUCTION |
AU2015201255B2 (en) * | 2008-01-14 | 2016-05-19 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2104698C1 (ru) * | 1991-12-23 | 1998-02-20 | Дзе Борд оф Сьюпервайзорз оф Луизиана Стейт Юниверсити энд Эгрикалчурал энд Мекэникал Колледж | Способ лечения патологических отклонений при диабете типа ii |
-
1997
- 1997-05-06 EP EP97923573A patent/EP0934069B1/en not_active Expired - Lifetime
- 1997-05-06 ES ES97923573T patent/ES2277357T3/es not_active Expired - Lifetime
- 1997-05-06 PT PT97923573T patent/PT934069E/pt unknown
- 1997-05-06 AT AT97923573T patent/ATE344668T1/de not_active IP Right Cessation
- 1997-05-06 DE DE69736928T patent/DE69736928T2/de not_active Expired - Lifetime
- 1997-05-06 CA CA002254116A patent/CA2254116C/en not_active Expired - Fee Related
- 1997-05-06 ES ES06015512T patent/ES2393303T3/es not_active Expired - Lifetime
- 1997-05-06 EP EP06015512A patent/EP1776955B1/en not_active Expired - Lifetime
- 1997-05-06 WO PCT/US1997/007701 patent/WO1997041873A1/en active IP Right Grant
- 1997-05-06 DK DK97923573T patent/DK0934069T3/da active
-
2007
- 2007-10-09 HK HK07110914.5A patent/HK1108312A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1776955B1 (en) | 2012-08-15 |
EP0934069A4 (en) | 2002-12-04 |
ES2393303T3 (es) | 2012-12-20 |
DK0934069T3 (da) | 2007-03-19 |
EP0934069B1 (en) | 2006-11-08 |
DE69736928T2 (de) | 2007-06-28 |
EP1776955A1 (en) | 2007-04-25 |
CA2254116A1 (en) | 1997-11-13 |
EP0934069A1 (en) | 1999-08-11 |
WO1997041873A1 (en) | 1997-11-13 |
PT934069E (pt) | 2007-02-28 |
ATE344668T1 (de) | 2006-11-15 |
ES2277357T3 (es) | 2007-07-01 |
CA2254116C (en) | 2009-10-20 |
DE69736928D1 (de) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1108312A1 (en) | Medical use and composition for the treatment of lipid and glucose metabolism disorders | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
MX9700030A (es) | Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos. | |
DE69531457D1 (en) | Sulfonamide | |
PT1235787E (pt) | Receptores agonistas beta2 adrenergicos | |
GEP20032958B (en) | Adenosine Derivatives | |
HK1044333A1 (zh) | 趨化因子受體拮抗劑及其使用方法 | |
BG106104A (en) | Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation | |
GR3030371T3 (en) | Triazole compounds and their use as dopamine-d 3?-ligands | |
EP0793489A4 (en) | AGENTS FOR TREATING SKIN DISEASES | |
WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
BG104008A (en) | Insulin resistance tretment with growth hormone secretagogues | |
SE9803760D0 (sv) | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel | |
BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
BG105539A (en) | Eletriptan hydrobromide monohydrate | |
HUT73231A (en) | Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis | |
MY142646A (en) | Chemokine receptor antagonists and methods of use therefor | |
DK0669826T3 (da) | (-)-Metrifonatholdigt lægemiddel | |
NZ336362A (en) | Use of a 15-keto-prostaglandin compound as a portal hypertension inhibitor | |
SE9604789D0 (sv) | New Compounds | |
IL158698A0 (en) | Agent for improving tissue penetration | |
MX9802104A (es) | Composiciones que usan un agonista de rxr solo o en combinacion con un agonista de ppar, para tratar diabetes mellitus no dependiente de insulina. | |
HUT72329A (en) | Application of riluzole as a radiorestorer | |
MY108739A (en) | Imidazole, triazole and tetrazole derivatives | |
MY128351A (en) | ß2-ADRENERGIC RECEPTOR AGONISTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160506 |